China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu,… Read more
China SXT Pharmaceuticals Inc (SXTC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.032x
Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) has a cash flow conversion efficiency ratio of -0.032x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-494.08K) by net assets ($15.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
China SXT Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how China SXT Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
China SXT Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China SXT Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DOLLAR TREE - Dusseldorf Stock Exchang
DU:DT3
|
0.042x |
|
Heads UP Ventures Limited
NSE:HEADSUP
|
0.002x |
|
Avgol Industries 1953 Ltd
TA:AVGL
|
0.038x |
|
Infomedia Press Limited
NSE:INFOMEDIA
|
-0.001x |
|
BELMONT RES INC.
F:L3L2
|
N/A |
|
Royal Orchid Hotel (Thailand) Public Company Limited
BK:ROH
|
-0.003x |
|
La Finca Global Assets SOCIMI S.A.
MC:YLFG
|
0.137x |
|
TAISEI
MU:TKK1
|
N/A |
Annual Cash Flow Conversion Efficiency for China SXT Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of China SXT Pharmaceuticals Inc from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $15.44 Million | $-2.35 Million | -0.152x | -9.75% |
| 2024-03-31 | $13.93 Million | $-1.93 Million | -0.138x | -2417.87% |
| 2023-03-31 | $14.69 Million | $-80.76K | -0.005x | -133.65% |
| 2022-03-31 | $16.42 Million | $268.29K | 0.016x | +119.80% |
| 2021-03-31 | $15.96 Million | $-1.32 Million | -0.082x | -183.00% |
| 2020-03-31 | $9.40 Million | $934.25K | 0.099x | +361.48% |
| 2019-03-31 | $11.11 Million | $239.19K | 0.022x | -96.32% |
| 2018-03-31 | $3.29 Million | $1.92 Million | 0.584x | +269.46% |
| 2017-03-31 | $1.85 Million | $293.04K | 0.158x | -35.61% |
| 2016-03-31 | $742.77K | $182.47K | 0.246x | -- |